




FIG. 1





FIG. 2

3 / 10



- Group 1 - Vehicle, PO BID
- Group 2 - 10/kg Retifanlimab, IP BIW
- ▲ Group 3 - 30mg/kg Compound 1, PO BID
- ▼ Group 4 - 100mg/kg Compound 1, PO QD
- △ Group 5 - 30mg/kg Compound 1 BID & Retifanlimab
- ▽ Group 6 - 100mg/kg Compound 1 QD & Retifanlimab

FIG. 3





FIG. 4



Group	Day 25			
	Day 25	% Inhibition	PR	CR
Group 1 - Vehicle, PO BID	2027.74		0	0
Group 2 - 25mg/kg Compound 2, PO BID	1683.64	17	0	0
Group 3 - 30mg/kg Compound 1, PO BID	1361.4	33	0	0
Group 4 - 100mg/kg Compound 1, PO QD **	775.06	62	0	0
Group 5 - Compound 2 & 30mg/kg Compound 1 *	1191	41	0	0
Group 6 - Compound 2 & 100mg/kg Compound 1 ***	378.46	81	1	1

FIG. 5




FIG. 6

6 / 10




FIG. 7




FIG. 8






FIG. 9

2838c3 (also known as KPCY-013) cell-line derived tumors established subcutaneously in C57BL/6 mice were treated with ±Compound 1 ±anti-PD-1 (Clone RMP1-14). In the survival analysis, endpoint was recorded when tumors reached 1500 mm³ or otherwise met humane endpoints




2838c3 (also known as KPCY-013) cell-line derived tumors established subcutaneously in C57BL/6 mice were treated with $\pm$ Compound 1 $\pm$ anti-PD-1 (Clone 10F.9G2). In the survival analysis, endpoint was recorded when tumors reached 1500 mm³ or otherwise met humane endpoints

FIG. 10



h-PDL1^{knock-in}/h-PDL1^{knock-out}/m-PDL1^{knock-out} mice bearing subcutaneous CT26-hPDL1^{knock-in}/mPDL1^{knock-out} (CT26 clone 299) tumors were treated with ±Compound 3 ±Compound 2 as indicated.

FIG. 11



h-PDL1^{knock-in}/h-PDL1^{knock-out}/m-PDL1^{knock-out}/m-PDL1^{knock-out} mice bearing subcutaneous CT26-hPDL1^{knock-in}/mPDL1^{knock-out} (CT26 clone 299) tumors were treated with ±Compound 3 ±Retifanlimab as indicated.

FIG. 12